As ri­vals press in, Stan­ford spin­out Forty Sev­en bur­nish­es its prospects from an im­pres­sive PhIb

Irv Weiss­man’s an­ti-CD47 can­cer drug is in the spot­light to­day with ear­ly but re­mark­able da­ta pub­lished in the NE­JM to un­der­score its po­ten­tial as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.